nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—liver cancer—vascular cancer	0.597	0.638	CtDrD
Sorafenib—kidney cancer—vascular cancer	0.339	0.362	CtDrD
Sorafenib—STK10—renal vein—vascular cancer	0.0123	0.425	CbGeAlD
Sorafenib—TIE1—blood vessel—vascular cancer	0.00207	0.0713	CbGeAlD
Sorafenib—FLT4—blood vessel—vascular cancer	0.00171	0.059	CbGeAlD
Sorafenib—FLT1—blood vessel—vascular cancer	0.00133	0.0458	CbGeAlD
Sorafenib—KDR—blood vessel—vascular cancer	0.00112	0.0388	CbGeAlD
Sorafenib—KIT—blood vessel—vascular cancer	0.000997	0.0343	CbGeAlD
Sorafenib—PDGFRB—blood vessel—vascular cancer	0.000973	0.0335	CbGeAlD
Sorafenib—HIPK3—cardiac atrium—vascular cancer	0.000896	0.0309	CbGeAlD
Sorafenib—TIE1—cardiac atrium—vascular cancer	0.000837	0.0288	CbGeAlD
Sorafenib—FGFR1—cardiac atrium—vascular cancer	0.000683	0.0235	CbGeAlD
Sorafenib—MAP3K7—cardiac atrium—vascular cancer	0.000646	0.0223	CbGeAlD
Sorafenib—MKNK2—cardiac atrium—vascular cancer	0.000626	0.0216	CbGeAlD
Sorafenib—MKNK1—cardiac atrium—vascular cancer	0.000618	0.0213	CbGeAlD
Sorafenib—RALBP1—cardiac atrium—vascular cancer	0.000566	0.0195	CbGeAlD
Sorafenib—FLT1—cardiac atrium—vascular cancer	0.000538	0.0185	CbGeAlD
Sorafenib—RAF1—cardiac atrium—vascular cancer	0.000535	0.0184	CbGeAlD
Sorafenib—EPHB6—cardiac atrium—vascular cancer	0.000532	0.0183	CbGeAlD
Sorafenib—MAP2K5—cardiac atrium—vascular cancer	0.000455	0.0157	CbGeAlD
Sorafenib—KDR—cardiac atrium—vascular cancer	0.000455	0.0157	CbGeAlD
Sorafenib—CSF1R—cardiac atrium—vascular cancer	0.000444	0.0153	CbGeAlD
Sorafenib—PDGFRB—cardiac atrium—vascular cancer	0.000394	0.0136	CbGeAlD
Sorafenib—ABCB1—blood vessel—vascular cancer	0.00027	0.0093	CbGeAlD
Sorafenib—FGFR1—Constitutive PI3K/AKT Signaling in Cancer—TSC2—vascular cancer	0.00018	0.00506	CbGpPWpGaD
Sorafenib—PDGFRA—Constitutive PI3K/AKT Signaling in Cancer—TSC2—vascular cancer	0.000179	0.00505	CbGpPWpGaD
Sorafenib—RAF1—mTOR signaling pathway—TSC2—vascular cancer	0.000178	0.00501	CbGpPWpGaD
Sorafenib—FGFR1—IRS-related events—TSC2—vascular cancer	0.000176	0.00497	CbGpPWpGaD
Sorafenib—FGFR1—IRS-related events triggered by IGF1R—TSC2—vascular cancer	0.000175	0.00493	CbGpPWpGaD
Sorafenib—KIT—PI-3K cascade—TSC2—vascular cancer	0.00017	0.00481	CbGpPWpGaD
Sorafenib—FGFR1—Insulin receptor signalling cascade—TSC2—vascular cancer	0.00017	0.0048	CbGpPWpGaD
Sorafenib—FGFR1—IGF1R signaling cascade—TSC2—vascular cancer	0.00017	0.0048	CbGpPWpGaD
Sorafenib—EPHX2—Metabolism—WWTR1—vascular cancer	0.000168	0.00473	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways in Glioblastoma—TSC2—vascular cancer	0.000168	0.00473	CbGpPWpGaD
Sorafenib—KIT—PI3K/AKT activation—TSC2—vascular cancer	0.000166	0.00469	CbGpPWpGaD
Sorafenib—MAP2K5—BDNF signaling pathway—TSC2—vascular cancer	0.000166	0.00468	CbGpPWpGaD
Sorafenib—KIT—GAB1 signalosome—TSC2—vascular cancer	0.000165	0.00465	CbGpPWpGaD
Sorafenib—MKNK1—Disease—WWTR1—vascular cancer	0.000163	0.0046	CbGpPWpGaD
Sorafenib—FGFR1—PI-3K cascade—TSC2—vascular cancer	0.000162	0.00456	CbGpPWpGaD
Sorafenib—PDGFRB—Constitutive PI3K/AKT Signaling in Cancer—TSC2—vascular cancer	0.000161	0.00455	CbGpPWpGaD
Sorafenib—PDGFRA—PI-3K cascade—TSC2—vascular cancer	0.000161	0.00455	CbGpPWpGaD
Sorafenib—KIT—Role of LAT2/NTAL/LAB on calcium mobilization—TSC2—vascular cancer	0.000161	0.00455	CbGpPWpGaD
Sorafenib—FGFR1—PI3K/AKT activation—TSC2—vascular cancer	0.000158	0.00445	CbGpPWpGaD
Sorafenib—PDGFRA—PI3K/AKT activation—TSC2—vascular cancer	0.000157	0.00444	CbGpPWpGaD
Sorafenib—FGFR1—GAB1 signalosome—TSC2—vascular cancer	0.000157	0.00442	CbGpPWpGaD
Sorafenib—PDGFRA—GAB1 signalosome—TSC2—vascular cancer	0.000156	0.00441	CbGpPWpGaD
Sorafenib—FGFR1—Role of LAT2/NTAL/LAB on calcium mobilization—TSC2—vascular cancer	0.000153	0.00432	CbGpPWpGaD
Sorafenib—PDGFRA—Role of LAT2/NTAL/LAB on calcium mobilization—TSC2—vascular cancer	0.000153	0.00431	CbGpPWpGaD
Sorafenib—MAP2K5—Insulin Signaling—TSC2—vascular cancer	0.000152	0.0043	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways in Glioblastoma—TSC2—vascular cancer	0.000149	0.00421	CbGpPWpGaD
Sorafenib—PDGFRB—PI-3K cascade—TSC2—vascular cancer	0.000145	0.0041	CbGpPWpGaD
Sorafenib—RAF1—IRS-mediated signalling—TSC2—vascular cancer	0.000145	0.00409	CbGpPWpGaD
Sorafenib—PDGFRB—PI3K/AKT activation—TSC2—vascular cancer	0.000142	0.004	CbGpPWpGaD
Sorafenib—FGFR1—Signaling by Insulin receptor—TSC2—vascular cancer	0.000141	0.00399	CbGpPWpGaD
Sorafenib—RAF1—IRS-related events—TSC2—vascular cancer	0.000141	0.00398	CbGpPWpGaD
Sorafenib—PDGFRB—GAB1 signalosome—TSC2—vascular cancer	0.000141	0.00397	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—WWTR1—vascular cancer	0.00014	0.00396	CbGpPWpGaD
Sorafenib—RAF1—IRS-related events triggered by IGF1R—TSC2—vascular cancer	0.00014	0.00395	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—WWTR1—vascular cancer	0.000138	0.00389	CbGpPWpGaD
Sorafenib—PDGFRB—Role of LAT2/NTAL/LAB on calcium mobilization—TSC2—vascular cancer	0.000138	0.00388	CbGpPWpGaD
Sorafenib—RAF1—IGF1R signaling cascade—TSC2—vascular cancer	0.000136	0.00384	CbGpPWpGaD
Sorafenib—RAF1—Insulin receptor signalling cascade—TSC2—vascular cancer	0.000136	0.00384	CbGpPWpGaD
Sorafenib—BRAF—Integrated Breast Cancer Pathway—TSC2—vascular cancer	0.000132	0.00374	CbGpPWpGaD
Sorafenib—MAPK11—Insulin Signaling—TSC2—vascular cancer	0.000128	0.0036	CbGpPWpGaD
Sorafenib—KIT—Signaling by SCF-KIT—TSC2—vascular cancer	0.000127	0.00359	CbGpPWpGaD
Sorafenib—BRAF—Signaling by FGFR—TSC2—vascular cancer	0.000125	0.00353	CbGpPWpGaD
Sorafenib—MAP2K5—NGF signalling via TRKA from the plasma membrane—TSC2—vascular cancer	0.000124	0.00351	CbGpPWpGaD
Sorafenib—CDK7—Gene Expression—WWTR1—vascular cancer	0.000124	0.00349	CbGpPWpGaD
Sorafenib—KIT—Downstream signaling of activated FGFR—TSC2—vascular cancer	0.000122	0.00344	CbGpPWpGaD
Sorafenib—FGFR1—Signaling by SCF-KIT—TSC2—vascular cancer	0.000121	0.00341	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling by SCF-KIT—TSC2—vascular cancer	0.000121	0.0034	CbGpPWpGaD
Sorafenib—KIT—Signaling by ERBB4—TSC2—vascular cancer	0.00012	0.00338	CbGpPWpGaD
Sorafenib—BRAF—Signaling by FGFR in disease—TSC2—vascular cancer	0.000117	0.00329	CbGpPWpGaD
Sorafenib—FGFR1—Downstream signaling of activated FGFR—TSC2—vascular cancer	0.000116	0.00326	CbGpPWpGaD
Sorafenib—PDGFRA—Downstream signaling of activated FGFR—TSC2—vascular cancer	0.000115	0.00325	CbGpPWpGaD
Sorafenib—MAP3K7—Insulin Signaling—TSC2—vascular cancer	0.000115	0.00325	CbGpPWpGaD
Sorafenib—CDK7—Disease—WWTR1—vascular cancer	0.000115	0.00324	CbGpPWpGaD
Sorafenib—KIT—Downstream signal transduction—TSC2—vascular cancer	0.000115	0.00323	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—WWTR1—vascular cancer	0.000114	0.00322	CbGpPWpGaD
Sorafenib—KIT—Signaling by FGFR—TSC2—vascular cancer	0.000114	0.00321	CbGpPWpGaD
Sorafenib—FGFR1—Signaling by ERBB4—TSC2—vascular cancer	0.000114	0.00321	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling by ERBB4—TSC2—vascular cancer	0.000114	0.0032	CbGpPWpGaD
Sorafenib—KIT—Signaling by ERBB2—TSC2—vascular cancer	0.000113	0.0032	CbGpPWpGaD
Sorafenib—RAF1—Signaling by Insulin receptor—TSC2—vascular cancer	0.000113	0.00319	CbGpPWpGaD
Sorafenib—KIT—DAP12 signaling—TSC2—vascular cancer	0.000113	0.00318	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism of lipids and lipoproteins—WWTR1—vascular cancer	0.000111	0.00314	CbGpPWpGaD
Sorafenib—KIT—Downstream signaling events of B Cell Receptor (BCR)—TSC2—vascular cancer	0.000111	0.00314	CbGpPWpGaD
Sorafenib—MAP3K7—Downstream signaling events of B Cell Receptor (BCR)—TSC2—vascular cancer	0.000111	0.00314	CbGpPWpGaD
Sorafenib—FGFR1—Downstream signal transduction—TSC2—vascular cancer	0.000109	0.00307	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling by SCF-KIT—TSC2—vascular cancer	0.000109	0.00306	CbGpPWpGaD
Sorafenib—PDGFRA—Downstream signal transduction—TSC2—vascular cancer	0.000108	0.00306	CbGpPWpGaD
Sorafenib—FGFR1—Signaling by FGFR—TSC2—vascular cancer	0.000108	0.00305	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling by FGFR—TSC2—vascular cancer	0.000108	0.00304	CbGpPWpGaD
Sorafenib—FGFR1—Signaling by ERBB2—TSC2—vascular cancer	0.000108	0.00304	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling by ERBB2—TSC2—vascular cancer	0.000107	0.00303	CbGpPWpGaD
Sorafenib—FGFR1—DAP12 signaling—TSC2—vascular cancer	0.000107	0.00302	CbGpPWpGaD
Sorafenib—PDGFRA—DAP12 signaling—TSC2—vascular cancer	0.000107	0.00301	CbGpPWpGaD
Sorafenib—KIT—Signaling by FGFR in disease—TSC2—vascular cancer	0.000106	0.003	CbGpPWpGaD
Sorafenib—KIT—DAP12 interactions—TSC2—vascular cancer	0.000106	0.003	CbGpPWpGaD
Sorafenib—KIT—Fc epsilon receptor (FCERI) signaling—TSC2—vascular cancer	0.000106	0.003	CbGpPWpGaD
Sorafenib—MAP3K7—Fc epsilon receptor (FCERI) signaling—TSC2—vascular cancer	0.000106	0.003	CbGpPWpGaD
Sorafenib—FGFR1—Downstream signaling events of B Cell Receptor (BCR)—TSC2—vascular cancer	0.000106	0.00298	CbGpPWpGaD
Sorafenib—PDGFRA—Downstream signaling events of B Cell Receptor (BCR)—TSC2—vascular cancer	0.000105	0.00297	CbGpPWpGaD
Sorafenib—KIT—Signaling by EGFR—TSC2—vascular cancer	0.000105	0.00297	CbGpPWpGaD
Sorafenib—KIT—Signaling by EGFR in Cancer—TSC2—vascular cancer	0.000104	0.00294	CbGpPWpGaD
Sorafenib—MAPK11—NGF signalling via TRKA from the plasma membrane—TSC2—vascular cancer	0.000104	0.00294	CbGpPWpGaD
Sorafenib—PDGFRB—Downstream signaling of activated FGFR—TSC2—vascular cancer	0.000104	0.00293	CbGpPWpGaD
Sorafenib—KIT—Signaling by PDGF—TSC2—vascular cancer	0.000104	0.00293	CbGpPWpGaD
Sorafenib—BRAF—NGF signalling via TRKA from the plasma membrane—TSC2—vascular cancer	0.000103	0.00291	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—WWTR1—vascular cancer	0.000103	0.0029	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling by ERBB4—TSC2—vascular cancer	0.000102	0.00289	CbGpPWpGaD
Sorafenib—FGFR1—DAP12 interactions—TSC2—vascular cancer	0.000101	0.00284	CbGpPWpGaD
Sorafenib—FGFR1—Signaling by FGFR in disease—TSC2—vascular cancer	0.000101	0.00284	CbGpPWpGaD
Sorafenib—FGFR1—Fc epsilon receptor (FCERI) signaling—TSC2—vascular cancer	0.000101	0.00284	CbGpPWpGaD
Sorafenib—PDGFRA—DAP12 interactions—TSC2—vascular cancer	0.000101	0.00284	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling by FGFR in disease—TSC2—vascular cancer	0.000101	0.00284	CbGpPWpGaD
Sorafenib—PDGFRA—Fc epsilon receptor (FCERI) signaling—TSC2—vascular cancer	0.000101	0.00284	CbGpPWpGaD
Sorafenib—FGFR1—Signaling by EGFR—TSC2—vascular cancer	9.99e-05	0.00282	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling by EGFR—TSC2—vascular cancer	9.96e-05	0.00281	CbGpPWpGaD
Sorafenib—FGFR1—Signaling by EGFR in Cancer—TSC2—vascular cancer	9.9e-05	0.00279	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling by EGFR in Cancer—TSC2—vascular cancer	9.87e-05	0.00278	CbGpPWpGaD
Sorafenib—FGFR1—Signaling by PDGF—TSC2—vascular cancer	9.86e-05	0.00278	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling by PDGF—TSC2—vascular cancer	9.83e-05	0.00277	CbGpPWpGaD
Sorafenib—KIT—B Cell Activation—TSC2—vascular cancer	9.83e-05	0.00277	CbGpPWpGaD
Sorafenib—MAP3K7—B Cell Activation—TSC2—vascular cancer	9.83e-05	0.00277	CbGpPWpGaD
Sorafenib—PDGFRB—Downstream signal transduction—TSC2—vascular cancer	9.77e-05	0.00276	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling by FGFR—TSC2—vascular cancer	9.72e-05	0.00274	CbGpPWpGaD
Sorafenib—RAF1—Signaling by SCF-KIT—TSC2—vascular cancer	9.68e-05	0.00273	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling by ERBB2—TSC2—vascular cancer	9.67e-05	0.00273	CbGpPWpGaD
Sorafenib—PDGFRB—DAP12 signaling—TSC2—vascular cancer	9.63e-05	0.00271	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling by NGF—TSC2—vascular cancer	9.57e-05	0.0027	CbGpPWpGaD
Sorafenib—RAF1—BDNF signaling pathway—TSC2—vascular cancer	9.52e-05	0.00269	CbGpPWpGaD
Sorafenib—PDGFRB—Downstream signaling events of B Cell Receptor (BCR)—TSC2—vascular cancer	9.49e-05	0.00268	CbGpPWpGaD
Sorafenib—KIT—NGF signalling via TRKA from the plasma membrane—TSC2—vascular cancer	9.41e-05	0.00265	CbGpPWpGaD
Sorafenib—EPHX2—Metabolism—HBA1—vascular cancer	9.39e-05	0.00265	CbGpPWpGaD
Sorafenib—FGFR1—B Cell Activation—TSC2—vascular cancer	9.33e-05	0.00263	CbGpPWpGaD
Sorafenib—PDGFRA—B Cell Activation—TSC2—vascular cancer	9.3e-05	0.00262	CbGpPWpGaD
Sorafenib—RAF1—Downstream signaling of activated FGFR—TSC2—vascular cancer	9.26e-05	0.00261	CbGpPWpGaD
Sorafenib—MAP3K7—Adaptive Immune System—CD34—vascular cancer	9.15e-05	0.00258	CbGpPWpGaD
Sorafenib—KIT—Adaptive Immune System—CD34—vascular cancer	9.15e-05	0.00258	CbGpPWpGaD
Sorafenib—RAF1—Signaling by ERBB4—TSC2—vascular cancer	9.12e-05	0.00257	CbGpPWpGaD
Sorafenib—MAPK11—Gene Expression—WWTR1—vascular cancer	9.06e-05	0.00255	CbGpPWpGaD
Sorafenib—PDGFRB—Fc epsilon receptor (FCERI) signaling—TSC2—vascular cancer	9.06e-05	0.00255	CbGpPWpGaD
Sorafenib—PDGFRB—DAP12 interactions—TSC2—vascular cancer	9.06e-05	0.00255	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling by FGFR in disease—TSC2—vascular cancer	9.06e-05	0.00255	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling by EGFR—TSC2—vascular cancer	8.98e-05	0.00253	CbGpPWpGaD
Sorafenib—FGFR1—NGF signalling via TRKA from the plasma membrane—TSC2—vascular cancer	8.93e-05	0.00252	CbGpPWpGaD
Sorafenib—PDGFRA—NGF signalling via TRKA from the plasma membrane—TSC2—vascular cancer	8.9e-05	0.00251	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling by EGFR in Cancer—TSC2—vascular cancer	8.9e-05	0.00251	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling by PDGF—TSC2—vascular cancer	8.86e-05	0.0025	CbGpPWpGaD
Sorafenib—RAF1—Insulin Signaling—TSC2—vascular cancer	8.75e-05	0.00247	CbGpPWpGaD
Sorafenib—RAF1—Downstream signal transduction—TSC2—vascular cancer	8.71e-05	0.00246	CbGpPWpGaD
Sorafenib—FGFR1—Adaptive Immune System—CD34—vascular cancer	8.68e-05	0.00245	CbGpPWpGaD
Sorafenib—RAF1—Signaling by FGFR—TSC2—vascular cancer	8.66e-05	0.00244	CbGpPWpGaD
Sorafenib—PDGFRA—Adaptive Immune System—CD34—vascular cancer	8.66e-05	0.00244	CbGpPWpGaD
Sorafenib—RAF1—Signaling by ERBB2—TSC2—vascular cancer	8.62e-05	0.00243	CbGpPWpGaD
Sorafenib—RAF1—DAP12 signaling—TSC2—vascular cancer	8.58e-05	0.00242	CbGpPWpGaD
Sorafenib—PDGFRB—B Cell Activation—TSC2—vascular cancer	8.38e-05	0.00236	CbGpPWpGaD
Sorafenib—BRAF—Disease—WWTR1—vascular cancer	8.33e-05	0.00235	CbGpPWpGaD
Sorafenib—RAF1—Signaling by FGFR in disease—TSC2—vascular cancer	8.07e-05	0.00228	CbGpPWpGaD
Sorafenib—RAF1—DAP12 interactions—TSC2—vascular cancer	8.07e-05	0.00228	CbGpPWpGaD
Sorafenib—RAF1—Fc epsilon receptor (FCERI) signaling—TSC2—vascular cancer	8.07e-05	0.00228	CbGpPWpGaD
Sorafenib—MAPK11—Signaling by NGF—TSC2—vascular cancer	8.02e-05	0.00226	CbGpPWpGaD
Sorafenib—PDGFRB—NGF signalling via TRKA from the plasma membrane—TSC2—vascular cancer	8.02e-05	0.00226	CbGpPWpGaD
Sorafenib—RAF1—Signaling by EGFR—TSC2—vascular cancer	8e-05	0.00226	CbGpPWpGaD
Sorafenib—BRAF—Signaling by NGF—TSC2—vascular cancer	7.95e-05	0.00224	CbGpPWpGaD
Sorafenib—RAF1—Signaling by EGFR in Cancer—TSC2—vascular cancer	7.93e-05	0.00224	CbGpPWpGaD
Sorafenib—RAF1—Signaling by PDGF—TSC2—vascular cancer	7.89e-05	0.00223	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—CD34—vascular cancer	7.8e-05	0.0022	CbGpPWpGaD
Sorafenib—KIT—Disease—WWTR1—vascular cancer	7.58e-05	0.00214	CbGpPWpGaD
Sorafenib—KIT—Signaling by NGF—TSC2—vascular cancer	7.23e-05	0.00204	CbGpPWpGaD
Sorafenib—FGFR1—Disease—WWTR1—vascular cancer	7.2e-05	0.00203	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—WWTR1—vascular cancer	7.18e-05	0.00202	CbGpPWpGaD
Sorafenib—RAF1—NGF signalling via TRKA from the plasma membrane—TSC2—vascular cancer	7.15e-05	0.00202	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—WWTR1—vascular cancer	7.03e-05	0.00198	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—CD34—vascular cancer	6.95e-05	0.00196	CbGpPWpGaD
Sorafenib—FGFR1—Signaling by NGF—TSC2—vascular cancer	6.87e-05	0.00194	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—WWTR1—vascular cancer	6.85e-05	0.00193	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling by NGF—TSC2—vascular cancer	6.85e-05	0.00193	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—WWTR1—vascular cancer	6.47e-05	0.00182	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling by NGF—TSC2—vascular cancer	6.17e-05	0.00174	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—CD34—vascular cancer	6.15e-05	0.00174	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—WWTR1—vascular cancer	5.89e-05	0.00166	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—WWTR1—vascular cancer	5.87e-05	0.00165	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—WWTR1—vascular cancer	5.83e-05	0.00165	CbGpPWpGaD
Sorafenib—RAF1—Disease—WWTR1—vascular cancer	5.76e-05	0.00163	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—CD34—vascular cancer	5.55e-05	0.00156	CbGpPWpGaD
Sorafenib—KIT—Immune System—CD34—vascular cancer	5.55e-05	0.00156	CbGpPWpGaD
Sorafenib—RAF1—Signaling by NGF—TSC2—vascular cancer	5.5e-05	0.00155	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—WWTR1—vascular cancer	5.31e-05	0.0015	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—WWTR1—vascular cancer	5.31e-05	0.0015	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—CD34—vascular cancer	5.27e-05	0.00149	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—CD34—vascular cancer	5.25e-05	0.00148	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—WWTR1—vascular cancer	5.24e-05	0.00148	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—WWTR1—vascular cancer	5.04e-05	0.00142	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—WWTR1—vascular cancer	5.03e-05	0.00142	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—WWTR1—vascular cancer	4.96e-05	0.0014	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—WWTR1—vascular cancer	4.96e-05	0.0014	CbGpPWpGaD
Sorafenib—MKNK1—Disease—TSC2—vascular cancer	4.78e-05	0.00135	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—WWTR1—vascular cancer	4.78e-05	0.00135	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—CD34—vascular cancer	4.73e-05	0.00133	CbGpPWpGaD
Sorafenib—MAPK11—Innate Immune System—TSC2—vascular cancer	4.58e-05	0.00129	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—WWTR1—vascular cancer	4.53e-05	0.00128	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—WWTR1—vascular cancer	4.32e-05	0.00122	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CD34—vascular cancer	4.22e-05	0.00119	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—WWTR1—vascular cancer	4.21e-05	0.00119	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—WWTR1—vascular cancer	4.17e-05	0.00118	CbGpPWpGaD
Sorafenib—KIT—Innate Immune System—TSC2—vascular cancer	4.13e-05	0.00116	CbGpPWpGaD
Sorafenib—MAP3K7—Innate Immune System—TSC2—vascular cancer	4.13e-05	0.00116	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—TSC2—vascular cancer	4.1e-05	0.00116	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—WWTR1—vascular cancer	4.08e-05	0.00115	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—TSC2—vascular cancer	4.04e-05	0.00114	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—WWTR1—vascular cancer	4.04e-05	0.00114	CbGpPWpGaD
Sorafenib—MAP3K7—Adaptive Immune System—TSC2—vascular cancer	3.96e-05	0.00112	CbGpPWpGaD
Sorafenib—KIT—Adaptive Immune System—TSC2—vascular cancer	3.96e-05	0.00112	CbGpPWpGaD
Sorafenib—FGFR1—Innate Immune System—TSC2—vascular cancer	3.92e-05	0.0011	CbGpPWpGaD
Sorafenib—PDGFRA—Innate Immune System—TSC2—vascular cancer	3.91e-05	0.0011	CbGpPWpGaD
Sorafenib—FGFR1—Adaptive Immune System—TSC2—vascular cancer	3.76e-05	0.00106	CbGpPWpGaD
Sorafenib—PDGFRA—Adaptive Immune System—TSC2—vascular cancer	3.75e-05	0.00106	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—TSC2—vascular cancer	3.52e-05	0.000992	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—WWTR1—vascular cancer	3.48e-05	0.000983	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—TSC2—vascular cancer	3.38e-05	0.000953	CbGpPWpGaD
Sorafenib—CDK7—Disease—TSC2—vascular cancer	3.37e-05	0.000949	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—TSC2—vascular cancer	3.35e-05	0.000943	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—TSC2—vascular cancer	3.14e-05	0.000885	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—WWTR1—vascular cancer	3.09e-05	0.000871	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—WWTR1—vascular cancer	3.02e-05	0.000851	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—TSC2—vascular cancer	3.01e-05	0.000849	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—TSC2—vascular cancer	3.01e-05	0.000849	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—HBA1—vascular cancer	2.78e-05	0.000783	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—HBA1—vascular cancer	2.78e-05	0.000783	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—TSC2—vascular cancer	2.67e-05	0.000752	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—WWTR1—vascular cancer	2.61e-05	0.000737	CbGpPWpGaD
Sorafenib—BRAF—Disease—TSC2—vascular cancer	2.44e-05	0.000688	CbGpPWpGaD
Sorafenib—KIT—Immune System—TSC2—vascular cancer	2.4e-05	0.000678	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—TSC2—vascular cancer	2.4e-05	0.000678	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—HBA1—vascular cancer	2.36e-05	0.000665	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—HBA1—vascular cancer	2.34e-05	0.000659	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—WWTR1—vascular cancer	2.33e-05	0.000658	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—TSC2—vascular cancer	2.28e-05	0.000643	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—WWTR1—vascular cancer	2.28e-05	0.000642	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—TSC2—vascular cancer	2.27e-05	0.000642	CbGpPWpGaD
Sorafenib—KIT—Disease—TSC2—vascular cancer	2.22e-05	0.000626	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—WWTR1—vascular cancer	2.15e-05	0.000605	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—WWTR1—vascular cancer	2.13e-05	0.0006	CbGpPWpGaD
Sorafenib—FGFR1—Disease—TSC2—vascular cancer	2.11e-05	0.000594	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—TSC2—vascular cancer	2.1e-05	0.000592	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—TSC2—vascular cancer	2.06e-05	0.00058	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—TSC2—vascular cancer	2.05e-05	0.000578	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TSC2—vascular cancer	2e-05	0.000565	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—TSC2—vascular cancer	1.89e-05	0.000534	CbGpPWpGaD
Sorafenib—RAF1—Immune System—TSC2—vascular cancer	1.83e-05	0.000515	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—WWTR1—vascular cancer	1.82e-05	0.000513	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—HBA1—vascular cancer	1.73e-05	0.000487	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TSC2—vascular cancer	1.72e-05	0.000486	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TSC2—vascular cancer	1.71e-05	0.000481	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—HBA1—vascular cancer	1.69e-05	0.000476	CbGpPWpGaD
Sorafenib—RAF1—Disease—TSC2—vascular cancer	1.69e-05	0.000476	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TSC2—vascular cancer	1.55e-05	0.000438	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TSC2—vascular cancer	1.55e-05	0.000438	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TSC2—vascular cancer	1.47e-05	0.000416	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TSC2—vascular cancer	1.47e-05	0.000415	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—HBA1—vascular cancer	1.46e-05	0.000413	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—WWTR1—vascular cancer	1.4e-05	0.000396	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TSC2—vascular cancer	1.33e-05	0.000374	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—HBA1—vascular cancer	1.31e-05	0.000368	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—HBA1—vascular cancer	1.27e-05	0.000359	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TSC2—vascular cancer	1.26e-05	0.000356	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—HBA1—vascular cancer	1.2e-05	0.000339	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—HBA1—vascular cancer	1.19e-05	0.000336	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TSC2—vascular cancer	1.18e-05	0.000333	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TSC2—vascular cancer	1.02e-05	0.000288	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—HBA1—vascular cancer	1.02e-05	0.000287	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—HBA1—vascular cancer	7.85e-06	0.000221	CbGpPWpGaD
